• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Deep Track Capital Releases Investor Presentation on Dynavax Technologies

    5/6/25 8:00:00 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DVAX alert in real time by email

    Highlights Opportunity to Unlock Value With Enhanced Boardroom Objectivity

    Details How Deep Track's Independent Nominees Will Prioritize Shareholder-Aligned Capital Allocation Decisions and Help Set Value-Maximizing Strategy in the Boardroom

    Visit www.RefocusDVAX.com to Download the Full Presentation

    Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we") one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax", "DVAX" or the "Company"), with ownership of approximately 14.53% of the Company's outstanding shares, today released an investor presentation titled "The Path to Creating and Preserving Value at Dynavax."

    The full presentation can be downloaded by clicking here. For more information, including how to vote for Deep Track's four nominees using the WHITE proxy card, please visit www.RefocusDVAX.com.

    If you have any questions, require assistance in voting your WHITE proxy card, or need additional copies of Deep Track's proxy materials, please contact:

    Innisfree M&A Incorporated

    501 Madison Avenue, 20th Floor

    New York, New York 10022

    Stockholders call toll-free (877) 687-1865

    About Deep Track Capital

    Deep Track Capital is a Greenwich, Connecticut-based investment firm focused exclusively on the life sciences industry. We develop long term partnerships with management teams of leading innovative public and pre-IPO biotechnology companies. In addition to capital, we seek to invest our time and expertise, while leveraging our network for the benefit of our partners. We aim to lead transactions while building large syndicates, and also to invest in rounds led by other qualified investors.

    CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

    The information herein contains "forward-looking statements." Specific forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and include, without limitation, words such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "potential," "targets," "forecasts," "seeks," "could," "should" or the negative of such terms or other variations on such terms or comparable terminology. Similarly, statements that describe our objectives, plans or goals are forward-looking. Forward-looking statements are subject to various risks and uncertainties and assumptions. There can be no assurance that any idea or assumption herein is, or will be proven, correct. If one or more of the risks or uncertainties materialize, or if any of the underlying assumptions of Deep Track Capital, LP ("Deep Track") or any of the other participants in the proxy solicitation described herein prove to be incorrect, the actual results may vary materially from outcomes indicated by these statements. Accordingly, forward looking statements should not be regarded as a representation by Deep Track that the future plans, estimates or expectations contemplated will ever be achieved.

    Certain statements and information included herein may have been sourced from third parties. Deep Track does not make any representations regarding the accuracy, completeness or timeliness of such third party statements or information. Except as may be expressly set forth herein, permission to cite such statements or information has neither been sought nor obtained from such third parties. Any such statements or information should not be viewed as an indication of support from such third parties for the views expressed herein.

    Deep Track disclaims any obligation to update the information herein or to disclose the results of any revisions that may be made to any projected results or forward-looking statements herein to reflect events or circumstances after the date of such information, projected results or statements or to reflect the occurrence of anticipated or unanticipated events.

    CERTAIN INFORMATION CONCERNING THE PARTICIPANTS

    Deep Track and the other Participants (as defined below) have filed a definitive proxy statement and accompanying WHITE universal proxy card with the Securities and Exchange Commission (the "SEC") to be used to solicit proxies for, among other matters, the election of its slate of director nominees at the 2025 annual stockholders meeting (the "2025 Annual Meeting") of Dynavax Technologies Corporation, a Delaware corporation ("DVAX"). Shortly after filing its definitive proxy statement with the SEC, Deep Track furnished the definitive proxy statement and accompanying WHITE universal proxy card to some or all of the stockholders entitled to vote at the 2025 Annual Meeting.

    The participants in the proxy solicitation are Deep Track, Deep Track Biotechnology Master Fund, Ltd. (the "Record Stockholder"), David Kroin (all of the foregoing persons, collectively, the "Deep Track Parties"), Brett A. Erkman, Jeffrey S. Farrow, Michael Mullette and Donald J. Santel (such individuals, collectively with the Deep Track Parties, the "Participants"). As of the date hereof, the Deep Track Parties beneficially own an aggregate of 17,791,486 shares (the "Deep Track Shares") of the common stock, par value $0.001 per share, of DVAX (the "Common Stock"). The Deep Track Shares collectively represent approximately 14.53% of the outstanding shares of Common Stock based on 122,411,685 shares of Common Stock outstanding as of the record date for the 2025 Annual Meeting as reported in DVAX's Definitive Proxy Statement filed with the SEC on April 17, 2025. Each of the Deep Track Parties may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Deep Track Shares. As of the date hereof, none of the other Participants beneficially own any shares of Common Stock.

    IMPORTANT INFORMATION AND WHERE TO FIND IT

    DEEP TRACK STRONGLY ADVISES ALL STOCKHOLDERS OF DVAX TO READ THE DEFINITIVE PROXY STATEMENT, ANY AMENDMENTS OR SUPPLEMENTS TO SUCH PROXY STATEMENT, AND OTHER PROXY MATERIALS FILED BY DEEP TRACK WITH THE SEC BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEBSITE AT WWW.SEC.GOV. THE DEFINITIVE PROXY STATEMENT, WHEN FILED, AND OTHER RELEVANT DOCUMENTS, WILL ALSO BE AVAILABLE BY DIRECTING A REQUEST TO THE PARTICIPANTS' PROXY SOLICITOR, INNISFREE M&A INCORPORATED, 501 MADISON AVENUE, 20th FLOOR, NEW YORK, NY 10022 (STOCKHOLDERS CAN CALL TOLL-FREE: (877)-687-1865).

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250506721048/en/

    Investor Contact

    Innisfree M&A Incorporated

    Scott Winter / Gabrielle Wolf

    +1 212-750-5833



    Media Contact

    Longacre Square Partners

    [email protected]

    Get the next $DVAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DVAX

    DatePrice TargetRatingAnalyst
    2/11/2025$15.00 → $12.00Neutral → Sell
    Goldman
    2/1/2024$20.00Neutral
    Goldman
    9/27/2022$22.00Mkt Outperform
    JMP Securities
    1/6/2022$38.00Buy
    Goldman
    12/29/2021$23.00 → $28.00Buy
    HC Wainwright & Co.
    8/31/2021$20.00 → $23.00Buy
    HC Wainwright & Co.
    8/6/2021$19.00Buy
    Goldman Sachs
    8/5/2021$16.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DVAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dynavax to Participate at the 8th Annual Evercore Healthcare Conference

    EMERYVILLE, Calif., Nov. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2nd at 2:10 p.m. ET. The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. About DynavaxDynavax is a

    11/19/25 4:01:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

    HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; reiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 millionBoard of Directors authorizes new $100 million share repurchase program Positive topline Phase 1/2 shingles vaccine trial data presented in late-breaker session at IDWeek Enters exclusive license agreement for Vaxart's novel oral COVID-19 vaccine program, expanding pipeline opportunitiesConference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Nov. 5, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vacc

    11/5/25 4:01:00 PM ET
    $DVAX
    $VXRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

    Collaboration positioned to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered COVID-19 vaccine options Vaxart to continue leading and funding development through Phase 2b completion and End of Phase 2 meeting with FDA; Dynavax to receive exclusive, worldwide license and right to assume responsibility for continued clinical development and commercialization following Phase 2b clinical developmentVaxart will receive a $25 million upfront payment and a $5 million equity investment from Dynavax, along with additional potential milestone-based payments and royalties contingent on Dynavax advancing the program post-Pha

    11/5/25 4:00:00 PM ET
    $DVAX
    $VXRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $DVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Myers Scott Dunseth bought $41,116 worth of shares (3,800 units at $10.82), increasing direct ownership by 12% to 35,004 units (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    8/25/25 8:50:44 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Deep Track Biotechnology Master Fund, Ltd. sold $22,351,598 worth of shares (2,065,137 units at $10.82) (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    8/22/25 8:49:18 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Silvernail Lauren P was granted 1,439 shares, increasing direct ownership by 17% to 10,075 units (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    6/13/25 5:55:43 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Myers Scott Dunseth bought $41,116 worth of shares (3,800 units at $10.82), increasing direct ownership by 12% to 35,004 units (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    8/25/25 8:50:44 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dynavax downgraded by Goldman with a new price target

    Goldman downgraded Dynavax from Neutral to Sell and set a new price target of $12.00 from $15.00 previously

    2/11/25 7:05:05 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Dynavax with a new price target

    Goldman initiated coverage of Dynavax with a rating of Neutral and set a new price target of $20.00

    2/1/24 6:20:13 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities initiated coverage on Dynavax with a new price target

    JMP Securities initiated coverage of Dynavax with a rating of Mkt Outperform and set a new price target of $22.00

    9/27/22 7:39:04 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    SEC Filings

    View All

    SEC Form 10-Q filed by Dynavax Technologies Corporation

    10-Q - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

    11/5/25 4:08:35 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dynavax Technologies Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

    11/5/25 4:02:30 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Dynavax Technologies Corporation

    8-K - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

    10/16/25 6:01:52 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Financials

    Live finance-specific insights

    View All

    Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

    HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; reiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 millionBoard of Directors authorizes new $100 million share repurchase program Positive topline Phase 1/2 shingles vaccine trial data presented in late-breaker session at IDWeek Enters exclusive license agreement for Vaxart's novel oral COVID-19 vaccine program, expanding pipeline opportunitiesConference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Nov. 5, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vacc

    11/5/25 4:01:00 PM ET
    $DVAX
    $VXRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025

    EMERYVILLE, Calif., Oct. 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Wednesday, November 5, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://in

    10/22/25 4:01:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dynavax Reports Second Quarter 2025 Financial Results

    Record HEPLISAV-B® quarterly net product revenue of $92 million, representing 31% year-over-year growthRefines full year 2025 HEPLISAV-B net product revenue guidance range to $315 to $325 million, from $305 to $325 millionTop-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in August 2025Completed dosing in Part 1 of Phase 1/2 trial of pandemic influenza adjuvant programConference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Aug. 7, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update

    8/7/25 4:00:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Leadership Updates

    Live Leadership Updates

    View All

    Deep Track Capital Comments on ISS Recommendation

    Strongly Disagrees with Recommendation and Believes ISS Ignored Key Issues in Its Incomplete Analysis ISS Has Chosen Not to Hold the Board Accountable for Its Underperformance in Recent Years, Heplisav's Waning Market Share Growth and Poor Corporate Governance Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax", "DVAX" or the "Company"), with ownership of approximately 14.82% of the Company's outstanding shares, today issued the following statement in response to a report issued by Instit

    5/23/25 6:12:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees

    ISS Recognizes There is No Case for Change Dynavax's Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value Dynavax Comments on Deep Track's Misleading Supplemental Materials Urges Stockholders to Follow ISS Recommendation and Vote "FOR" ALL Four of Dynavax's Highly Qualified Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif., May 23, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that leading independent proxy advisory firm, Institutional Shareholder Services ("ISS

    5/23/25 1:44:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    /C O R R E C T I O N -- Dynavax Technologies/

    In the news release, Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum, issued 07-May-2025 by Dynavax Technologies over PR Newswire, we are advised by the company that the second paragraph, second sentence of the stockholder letter should read "Dynavax has generated over $900 million of stockholder value, returning over 62% versus the S&P Biotechnology Select Industry Index's return of -7%[2]." rather than "Dynavax has generated approximately $1 billion of stockholder value, returning over 104% versus the S&P Biotechnology Select Industry Index's return of only 14%[2]." as originally issued inadvertently. The complete, corre

    5/7/25 4:45:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Dynavax Technologies Corporation

    SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

    11/14/24 12:18:08 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Dynavax Technologies Corporation

    SC 13D/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

    10/24/24 4:06:57 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dynavax Technologies Corporation

    SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

    10/16/24 9:37:13 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care